Prosecution Insights
Last updated: July 17, 2026
Application No. 18/363,760

DEGRADABLE DUAL-COMPONENT HYDROGEL AND ITS PREPARATION AND APPLICATIONS

Non-Final OA §102
Filed
Aug 02, 2023
Priority
Feb 09, 2021 — CN 202110174135.X +1 more
Examiner
FUBARA, BLESSING M
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Lingel Medical Technology Co. Ltd.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
3m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
795 granted / 1281 resolved
+2.1% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
40 currently pending
Career history
1319
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
47.5%
+7.5% vs TC avg
§102
6.3%
-33.7% vs TC avg
§112
5.5%
-34.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1281 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged for IDS filed 08/02/2023 and response to restriction requirement filed 04/23/2026. Claims 1-15 are pending. Election/Restrictions In response to the restriction requirement mailed 02/25/2026, applicant elected Group I, claims 1-9 and elected degradable structure terminated with polyethylene glycol as the polymer P; and elected specific component A-1.1 listed in paragraph [0036] of the as filed specification: PNG media_image1.png 137 400 media_image1.png Greyscale . Based on this election, applicant identified claims 1-5 as reading on the elected species and withdraws claims 6-15. Applicant further requested that upon the allowance of claims 1-5, the withdrawn claims be rejoined with allowable claim 1. Applicant does not indicate that the election is made with or without traverse ad has not provided reasons for traversal. Therefore, applicant’s election of Group I, claims 1-5 in the reply filed on 04/23/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 6-15 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 04/23/2026. Claims 1-5 are under consideration. While applicant elected claims 1-5 and the specific component A-1.1, no claim is amended. Priority This application is a continuation of PCT/CN2021/091377 filed 04/30/2021 and which claim benefit of Chinese application 202110174135.X filed 02/09/2021. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-4 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by HE CHAOLIANG et al., (CN 111440334 (A) cited in 1449, using the Espacenet English Translation). No claim is amended. Claim 1 teaches o-phthalaldehyde modified polymer and one of the polymers is multi-arm PEG. For claim 1 and 2 and 4, HE CHAOLIANG teaches tetra-arm (multi-arm) polyethylene glycol with o-phthalaldehyde (See the whole document with emphasis on Figure, paragraph [0041]; last two lines of paragraph [0119]; lines 4 and 5 of paragraph [0121]; paragraph [0154]; paragraph [0157], paragraph [0159]-[0160]; line 5 of paragraphs [0162], [0164], [0166], [0168], [0170], [0172], [0176], [0178], [0180] (line 6), [0184]); all of the English translated document. On page 2 of 3 of the original CN 111440334 (A) document, compounds (IV) and (V) disclose 4-arm and 8-arm modified PEG where the R is formula II, o-phthalaldehyde and n is greater than 2 in each of (IV) and (V). In component II, R1-R4 is each hydrogen meting structure of Formula I of claim 1 and which also meets the limitation of R5-and R6 of the structure of formula II of claim 2; and the polyethylene glycol meets claim 4. In paragraph [0055] of the original document, o-phthalaldehyde PNG media_image2.png 49 179 media_image2.png Greyscale has an amide bond and x + y is greater than 50 and less than 2500 (paragraph [0019] of the translation), thereby having polypeptide bond meeting claim 3. Therefore, HE CHAOLIANG teaches all the elements of claims 1-4. Allowable Subject Matter Claim 5 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The elected species is PNG media_image1.png 137 400 media_image1.png Greyscale is free of art. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached 7:30 am-6 pm (M-T). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian Yong Kwon can be reached at 5712720581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BLESSING M FUBARA/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Aug 02, 2023
Application Filed
Jun 11, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673051
COMPOSITION AND PRODUCT THEREOF
3y 9m to grant Granted Jul 07, 2026
Patent 12672868
Sutures with Expanded Antibacterial Properties
3y 2m to grant Granted Jul 07, 2026
Patent 12649669
METHOD FOR MICROORGANISM GROWTH INHIBITION
2y 5m to grant Granted Jun 09, 2026
Patent 12642882
DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
3y 5m to grant Granted Jun 02, 2026
Patent 12635719
DELAYED RELEASE SOFTGEL CAPSULES IN HIGHER PH ENVIRONMENT
1y 9m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
96%
With Interview (+34.0%)
3y 3m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1281 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month